ArticlePDF Available

Type I diabetes : A case report

Article

Type I diabetes : A case report

Abstract and Figures

case report of a juvenile diabetic patent by a 12 week treatment with Metadichol® a patent pending nano formulation of lipid alcohols as described in US patent publication US 12/691706 published Aug 26th 2010
Content may be subject to copyright.
ype 1 diabetes is an autoimmune disease that results from the
body's failure to produce insulin, the hormone that allows
glucose to enter the cells of the body to provide fuel. This is
the result of an autoimmune process in which the body's
immune system attacks and destroys the insulin producing
cells of the pancreas. When glucose cannot enter the cells, it
builds up in the blood and the body's cells literally starve.
People with type 1 diabetes must take daily insulin injections
and regularly monitor their blood sugar levels.
We like to report a case of a 27 year old male diagnosed with type 1
diabetes since age 3. His daily insulin use was 48 units (16 units
each for breakfast, lunch and dinner). He was treated with
Metadichol 1 (a US and International patent pending nano
formulation of long chain lipid alcohols). The ingredients in our
formulation are present in foods like rice, wheat, sugar cane and
many grains, which humans have consumed on a daily basis since
the dawn of civilization.
His daily dose of Metadichol was 40 mg (20 mg twice daily) and his
insulin and fasting blood glucose was monitored on a regular basis.
His fasting insulin levels are shown in Fig 1. From a baseline of 0.19
mU/L, his fasting level increased to 30 mU/L at week 60, an increase
of 150 fold from baseline values. His average fasting glucose level
decreased from 219 mg %to 121 mg % a decrease of 44% (fig 2)
Interestingly the C-peptide, a marker of endogenous beta cell activity
showed no change from 0.05 ng/ml. The only other notable change
was the marked change in A/G ratios that declined 37% from 1.6 at
base line to 1.02, at 60 weeks (fig 3). The major component Globulin
is gamma globulin that interestingly enough is used therapeutically
as IVIG in many autoimmune diseases.2
Given the fact that insulin has a very short half-life, any insulin that
was taken exogenously (approximately 16 units) the previous night
should not be present after 12 hour of fasting.
We have since tried this on another patient a juvenile diabetic
Female 17 years old (diagnosed at age 14) who is showing elevated
levels of fasting insulin from 0.6 mU/L at baseline to 8 mU/L after
10-12 weeks of Metadichol @ 40 mg per day and has not shown any
increase in C-peptide levels. More studies are on going to verify our
initial findings and will be the subject of future communications.
One can speculate that without a C-peptide increase,
Metadichol may be enhancing the half-life of Insulin, or there are
other pathways to insulin that do not have a role for C-peptide. More
studies are ongoing to prove the source of this insulin
Reference:
1) Metadichol US patent application no 12/691,706 and PCT/
US10/21684. Expected date of Publication Aug 26th 2010
2) M. D. KAZATCHKINE et al (1991), Intravenous
immunoglobulin’s (IVIg) in the treatment of autoimmune
diseases, Clin. Exp. Immunol. 86, 192-198.
FIG 1
Fasting insulin mU/L
!
Fig 2
Fasting Glucose mg %
!
Fig 3
A/G ratios
!
ResearchGate has not been able to resolve any citations for this publication.
ResearchGate has not been able to resolve any references for this publication.